

# Katherine A Hoadley

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2977425/katherine-a-hoadley-publications-by-year.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

139 papers	39,352 citations	73 h-index	153 g-index
153 ext. papers	53,036 ext. citations	16.5 avg, IF	5.94 L-index

#	Paper	IF	Citations
139	Racial differences in breast cancer outcomes by hepatocyte growth factor pathway expression.. <i>Breast Cancer Research and Treatment</i> , <b>2022</b> , 192, 447	4.4	
138	CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101506	2.2	7
137	BIDIMENSIONAL LINKED MATRIX FACTORIZATION FOR PAN-OMICS PAN-CANCER ANALYSIS.. <i>Annals of Applied Statistics</i> , <b>2022</b> , 16, 193-215	2.1	0
136	Spatial Characterization of Tumor-Infiltrating Lymphocytes and Breast Cancer Progression.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	2
135	Genomic characterization of rare molecular subclasses of hepatocellular carcinoma. <i>Communications Biology</i> , <b>2021</b> , 4, 1150	6.7	0
134	UNMASC: tumor-only variant calling with unmatched normal controls. <i>NAR Cancer</i> , <b>2021</b> , 3, zcab040	5.2	2
133	Proteogenomic and metabolomic characterization of human glioblastoma. <i>Cancer Cell</i> , <b>2021</b> , 39, 509-528.e20	24.3	71
132	Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4599-4609	12.9	4
131	Integrative modeling identifies genetic ancestry-associated molecular correlates in human cancer. <i>STAR Protocols</i> , <b>2021</b> , 2, 100483	1.4	0
130	Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features. <i>JNCI Cancer Spectrum</i> , <b>2021</b> , 5, pkaa072	4.6	3
129	Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. <i>Cancer Cell</i> , <b>2021</b> , 39, 38-53.e7	24.3	18
128	An approach for normalization and quality control for NanoString RNA expression data. <i>Briefings in Bioinformatics</i> , <b>2021</b> , 22,	13.4	15
127	SCISSOR: a framework for identifying structural changes in RNA transcripts. <i>Nature Communications</i> , <b>2021</b> , 12, 286	17.4	2
126	Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway. <i>Cell Reports</i> , <b>2021</b> , 34, 108707	10.6	7
125	Protein-based immune profiles of basal-like vs. luminal breast cancers. <i>Laboratory Investigation</i> , <b>2021</b> , 101, 785-793	5.9	2
124	Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. <i>Cancer Cell</i> , <b>2021</b> , 39, 361-379.e16	24.3	50
123	A proteogenomic portrait of lung squamous cell carcinoma. <i>Cell</i> , <b>2021</b> , 184, 4348-4371.e40	56.2	15

122	Hepatocyte growth factor pathway expression in breast cancer by race and subtype. <i>Breast Cancer Research</i> , <b>2021</b> , 23, 80	8.3	1
121	Proteogenomic characterization of pancreatic ductal adenocarcinoma. <i>Cell</i> , <b>2021</b> , 184, 5031-5052.e26	56.2	26
120	JOINT AND INDIVIDUAL ANALYSIS OF BREAST CANCER HISTOLOGIC IMAGES AND GENOMIC COVARIATES.. <i>Annals of Applied Statistics</i> , <b>2021</b> , 15, 1697-1722	2.1	2
119	A Pan-Cancer and Polygenic Bayesian Hierarchical Model for the Effect of Somatic Mutations on Survival. <i>Cancer Informatics</i> , <b>2020</b> , 19, 1176935120907399	2.4	1
118	Virus expression detection reveals RNA-sequencing contamination in TCGA. <i>BMC Genomics</i> , <b>2020</b> , 21, 79	4.5	6
117	Genomic basis for RNA alterations in cancer. <i>Nature</i> , <b>2020</b> , 578, 129-136	50.4	148
116	In silico APC/C substrate discovery reveals cell cycle-dependent degradation of UHRF1 and other chromatin regulators. <i>PLoS Biology</i> , <b>2020</b> , 18, e3000975	9.7	5
115	Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer. <i>Cancer Cell</i> , <b>2020</b> , 37, 639-654.e6	24.3	56
114	Gain-of-Function Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer. <i>Cancer Discovery</i> , <b>2020</b> , 10, 288-305	24.4	41
113	Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4184-4193	2.2	28
112	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. <i>European Urology</i> , <b>2020</b> , 77, 420-433	10.2	309
111	Prognostic value of B cells in cutaneous melanoma. <i>Genome Medicine</i> , <b>2019</b> , 11, 36	14.4	46
110	The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4644-4655	12.9	41
109	Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts. <i>Translational Oncology</i> , <b>2019</b> , 12, 661-668	4.9	8
108	FOXN1 Deubiquitination by USP21 Regulates Cell Cycle Progression and Paclitaxel Sensitivity in Basal-like Breast Cancer. <i>Cell Reports</i> , <b>2019</b> , 26, 3076-3086.e6	10.6	39
107	Before and After: Comparison of Legacy and Harmonized TCGA Genomic Data CommonsTData. <i>Cell Systems</i> , <b>2019</b> , 9, 24-34.e10	10.6	64
106	Genetic determinants of the molecular portraits of epithelial cancers. <i>Nature Communications</i> , <b>2019</b> , 10, 5666	17.4	8
105	PAM50 Molecular Intrinsic Subtypes in the NursesTHealth Study Cohorts. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2019</b> , 28, 798-806	4	8

104	Differences in race, molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas. <i>Cancer Causes and Control</i> , <b>2019</b> , 30, 31-39	2.8	7
103	The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 584	5.3	9
102	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. <i>Cell</i> , <b>2018</b> , 173, 400-416.e11	56.2	1072
101	Comprehensive Characterization of Cancer Driver Genes and Mutations. <i>Cell</i> , <b>2018</b> , 173, 371-385.e18	56.2	854
100	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. <i>Cell</i> , <b>2018</b> , 173, 291-304.e6	56.2	888
99	A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. <i>Cell</i> , <b>2018</b> , 173, 386-399.e12	56.2	133
98	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. <i>Cell</i> , <b>2018</b> , 173, 305-320.e10	56.2	166
97	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. <i>Cell</i> , <b>2018</b> , 173, 338-354.e15	56.2	560
96	Oncogenic Signaling Pathways in The Cancer Genome Atlas. <i>Cell</i> , <b>2018</b> , 173, 321-337.e10	56.2	1124
95	Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. <i>Cell Reports</i> , <b>2018</b> , 23, 282-296.e4	10.6	188
94	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. <i>Cell Reports</i> , <b>2018</b> , 23, 194-212.e6	10.6	146
93	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. <i>Cell Reports</i> , <b>2018</b> , 23, 313-326.e5	10.6	295
92	Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. <i>Cell Reports</i> , <b>2018</b> , 23, 181-193.e7	10.6	366
91	The Immune Landscape of Cancer. <i>Immunity</i> , <b>2018</b> , 48, 812-830.e14	32.3	1754
90	Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. <i>Cell Reports</i> , <b>2018</b> , 23, 213-226.e3	26.6	56
89	Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. <i>Cell Reports</i> , <b>2018</b> , 23, 239-254.e6	10.6	405
88	Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 726-733	9.7	27
87	Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 1845-1852	12.9	47

86	The Integrated Genomic Landscape of Thymic Epithelial Tumors. <i>Cancer Cell</i> , <b>2018</b> , 33, 244-258.e10	24.3	150
85	Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. <i>Nature Medicine</i> , <b>2018</b> , 24, 628-637	50.5	410
84	Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. <i>Cell Systems</i> , <b>2018</b> , 6, 271-281.e7	10.6	320
83	lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. <i>Cancer Cell</i> , <b>2018</b> , 33, 706-720.e9	24.3	275
82	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. <i>Cancer Cell</i> , <b>2018</b> , 33, 676-689.e3	24.3	377
81	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. <i>Cancer Cell</i> , <b>2018</b> , 33, 721-735.e8	24.3	228
80	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. <i>Cancer Cell</i> , <b>2018</b> , 33, 690-705.e9	24.3	277
79	National Cancer Institute Biospecimen Evidence-Based Practices: Harmonizing Procedures for Nucleic Acid Extraction from Formalin-Fixed, Paraffin-Embedded Tissue. <i>Biopreservation and Biobanking</i> , <b>2018</b> , 16, 247-250	2.1	7
78	Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. <i>Cancer Cell</i> , <b>2018</b> , 34, 211-224.e6	24.3	327
77	Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. <i>Cell Reports</i> , <b>2018</b> , 24, 1434-1444.e7	10.6	43
76	Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5292-5304	12.9	41
75	Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. <i>Oncotmunology</i> , <b>2018</b> , 7, e1490854	7.2	129
74	Integrated Molecular Characterization of Testicular Germ Cell Tumors. <i>Cell Reports</i> , <b>2018</b> , 23, 3392-3406.e10	10.6	200
73	Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 1371-1383	15.9	83
72	Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study. <i>Cancer Causes and Control</i> , <b>2018</b> , 29, 25-32	2.8	8
71	Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110,	9.7	62
70	The chromatin accessibility landscape of primary human cancers. <i>Science</i> , <b>2018</b> , 362,	33.3	392
69	Integrative Molecular Characterization of Malignant Pleural Mesothelioma. <i>Cancer Discovery</i> , <b>2018</b> , 8, 1548-1565	24.4	258

68	TP53 protein levels, RNA-based pathway assessment, and race among invasive breast cancer cases. <i>Npj Breast Cancer</i> , <b>2018</b> , 4, 13	7.8	9
67	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. <i>Cancer Cell</i> , <b>2017</b> , 31, 181-193	24.3	350
66	Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 162, 439-450	4.4	34
65	Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. <i>European Urology</i> , <b>2017</b> , 72, 544-554	10.2	411
64	Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. <i>JAMA Oncology</i> , <b>2017</b> , 3, 1654-1662	13.4	146
63	Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. <i>Cell</i> , <b>2017</b> , 169, 1327-1341.e23	56.2	1125
62	Age at diagnosis, obesity, smoking, and molecular subtypes in muscle-invasive bladder cancer. <i>Cancer Causes and Control</i> , <b>2017</b> , 28, 539-544	2.8	12
61	Integrated Molecular Characterization of Uterine Carcinosarcoma. <i>Cancer Cell</i> , <b>2017</b> , 31, 411-423	24.3	210
60	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. <i>Cell Reports</i> , <b>2017</b> , 18, 2780-2794	10.6	247
59	Nuclear Localized LSR: A Novel Regulator of Breast Cancer Behavior and Tumorigenesis. <i>Molecular Cancer Research</i> , <b>2017</b> , 15, 165-178	6.6	17
58	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. <i>Cell</i> , <b>2017</b> , 171, 540-556.e25	27.5	961
57	Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. <i>Cancer Cell</i> , <b>2017</b> , 32, 204-220.e15	24.3	391
56	Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. <i>Cancer Cell</i> , <b>2017</b> , 32, 185-203.e13	24.3	396
55	Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades. <i>JAMA Oncology</i> , <b>2017</b> , 3, 1503-1510	13.4	53
54	The molecular basis of breast cancer pathological phenotypes. <i>Journal of Pathology</i> , <b>2017</b> , 241, 375-391	9.4	62
53	Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set. <i>Npj Breast Cancer</i> , <b>2016</b> , 2,	7.8	200
52	Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting. <i>Bladder Cancer</i> , <b>2016</b> , 2, 37-47	4.7	134
51	Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	187

50	Identification of mRNA isoform switching in breast cancer. <i>BMC Genomics</i> , <b>2016</b> , 17, 181	4.5	19
49	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 135-45	59.2	753
48	Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 542-9	2.2	242
47	Subtyping sub-Saharan esophageal squamous cell carcinoma by comprehensive molecular analysis. <i>JCI Insight</i> , <b>2016</b> , 1, e88755	9.9	37
46	Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases. <i>PLoS Medicine</i> , <b>2016</b> , 13, e1002174	11.6	62
45	DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome Atlas. <i>Npj Breast Cancer</i> , <b>2016</b> , 2, 16007	7.8	25
44	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. <i>Cancer Cell</i> , <b>2016</b> , 29, 723-736	24.3	324
43	Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. <i>Nature Genetics</i> , <b>2016</b> , 48, 607-16	36.3	613
42	MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays. <i>Radiology</i> , <b>2016</b> , 281, 382-391	20.5	297
41	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 2481-98	59.2	1828
40	Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development. <i>Journal of Neurochemistry</i> , <b>2015</b> , 133, 730-8	6	10
39	Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. <i>Cell</i> , <b>2015</b> , 163, 506-19	56.2	1055
38	Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. <i>Nature Genetics</i> , <b>2015</b> , 47, 1168-78	36.3	893
37	Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents. <i>Cell Reports</i> , <b>2015</b> , 13, 2353-2361	10.6	115
36	Update on The Cancer Genome Atlas Project on Muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , <b>2015</b> , 1, 94-95	5.1	4
35	Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. <i>BMC Medicine</i> , <b>2015</b> , 13, 303	11.4	87
34	Abstract S3-06: Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer <b>2015</b> ,		3
33	Overexpression of miR-146a in basal-like breast cancer cells confers enhanced tumorigenic potential in association with altered p53 status. <i>Carcinogenesis</i> , <b>2014</b> , 35, 2567-75	4.6	37



32	Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. <i>Cell</i> , <b>2014</b> , 158, 929-944	56.2	935
31	Comparison of RNA-Seq by poly (A) capture, ribosomal RNA depletion, and DNA microarray for expression profiling. <i>BMC Genomics</i> , <b>2014</b> , 15, 419	4.5	204
30	Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status. <i>Breast Cancer Research and Treatment</i> , <b>2014</b> , 147, 185-91	4.4	33
29	Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 3110-5	11.5	537
28	Integrated RNA and DNA sequencing improves mutation detection in low purity tumors. <i>Nucleic Acids Research</i> , <b>2014</b> , 42, e107	20.1	59
27	Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 3818-29	12.9	168
26	The molecular diversity of Luminal A breast tumors. <i>Breast Cancer Research and Treatment</i> , <b>2013</b> , 141, 409-20	4.4	90
25	Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. <i>New England Journal of Medicine</i> , <b>2013</b> , 368, 2059-74	59.2	3137
24	Impact of tumor microenvironment and epithelial phenotypes on metabolism in breast cancer. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 571-85	12.9	73
23	JOINT AND INDIVIDUAL VARIATION EXPLAINED (JIVE) FOR INTEGRATED ANALYSIS OF MULTIPLE DATA TYPES. <i>Annals of Applied Statistics</i> , <b>2013</b> , 7, 523-542	2.1	239
22	Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 517-25	15.9	371
21	Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes. <i>PLoS ONE</i> , <b>2013</b> , 8, e56823	3.7	204
20	miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. <i>Neuro-Oncology</i> , <b>2012</b> , 14, 712-9	1	144
19	TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2615-23	2.2	359
18	Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. <i>PLoS ONE</i> , <b>2010</b> , 5, e10767	3.7	51
17	Potential tumor suppressor role for the c-Myb oncogene in luminal breast cancer. <i>PLoS ONE</i> , <b>2010</b> , 5, e13073	3.7	35
16	Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 4864-75	12.9	194
15	Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. <i>Cancer Cell</i> , <b>2010</b> , 17, 98-110	24.3	4782



14	Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. <i>Cancer Cell</i> , <b>2010</b> , 17, 510-22	24.3	1754
13	Molecular Signatures of Drug Resistance <b>2009</b> , 271-294		
12	Development of an immuno tandem mass spectrometry (iMALDI) assay for EGFR diagnosis. <i>Proteomics - Clinical Applications</i> , <b>2007</b> , 1, 1651-9	3.1	51
11	RNA expression analysis of formalin-fixed paraffin-embedded tumors. <i>Laboratory Investigation</i> , <b>2007</b> , 87, 383-91	5.9	136
10	EGFR associated expression profiles vary with breast tumor subtype. <i>BMC Genomics</i> , <b>2007</b> , 8, 258	4.5	208
9	Gene expression patterns associated with p53 status in breast cancer. <i>BMC Cancer</i> , <b>2006</b> , 6, 276	4.8	107
8	Prediction of toxicant-specific gene expression signatures after chemotherapeutic treatment of breast cell lines. <i>Environmental Health Perspectives</i> , <b>2004</b> , 112, 1607-13	8.4	12
7	Cell-type-specific responses to chemotherapeutics in breast cancer. <i>Cancer Research</i> , <b>2004</b> , 64, 4218-26	10.1	307
6	Prediction of Toxicant-Specific Gene Expression Signatures after Chemotherapeutic Treatment of Breast Cell Lines. <i>Environmental Health Perspectives</i> , <b>2004</b> , 112, 1607-1613	8.4	18
5	A Consensus Molecular Classification of Muscle-Invasive Bladder Cancer. <i>SSRN Electronic Journal</i> ,	1	8
4	Genomic basis for RNA alterations revealed by whole-genome analyses of 27 cancer types		10
3	An approach for normalization and quality control for NanoString RNA expression data		3
2	The consensus molecular classification of muscle-invasive bladder cancer		6
1	Tumor mutational landscape is a record of the pre-malignant state		8